Pada tahun 1992, solusi intravena disetujui untuk dipasarkan,<ref>{{cite journal | vauthors = Flor SC, Rogge MC, Chow AT | title = Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers | journal = Antimicrobial Agents and Chemotherapy | volume = 37 | issue = 7 | pages = 1468–1472 | date = July 1993 | pmid = 8363378 | pmc = 187996 | doi = 10.1128/aac.37.7.1468 }}</ref>
Pada tahun 1997, indikasi untuk [[penyakit radang panggulpelvis]] telah disetujui oleh Badan Pengawas Obat dan Makanan ASAmerika (FDA)Serikat untuk formulasi oral,<ref>{{cite web|series=Floxin Tablets New FDA Drug Approval | work = CenterWatch|url=https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/212/floxin-tablets-ofloxacin-tablets|title=Floxin Tablets (ofloxacin tablets) |access-date=August 25, 2016|url-status=live|archive-url=https://web.archive.org/web/20160413040722/http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/212/floxin-tablets-ofloxacin-tablets|archive-date=April 13, 2016}}</ref> dan pada tahun yang sama, solusi untuk infeksi telinga disetujui dengan merek tersebut.<ref>{{cite web|title=Floxin otic New FDA Drug Approval |url= http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/368/floxin-otic |url-status=live |archive-url= https://web.archive.org/web/20160827085637/http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/368/floxin-otic|archive-date=2016-08-27}}</ref>
Daiichi dan J&J juga melakukan kanibalisasi pasarnya sendiri dengan memperkenalkan levofloxacin[[levofloksasin]], levo-enansiomer ofloxacinofloksasin, pada tahun 1996;<ref name=Atarashi/> Penjualan tahunan Floxin oleh Johnson dan Johnson pada tahun 2003 adalah sekitar $30 juta, sedangkan penjualan gabungan Levaquin/Floxin mereka melebihi $1,15 miliar pada tahun yang sama.<ref>{{cite news |title=Teva Announces Approval of Ofloxacin Tablets, 200 mg, 300 mg, and 400 mg |url=http://findarticles.com/p/articles/mi_m0EIN/is_2003_Sept_2/ai_107154169/ |date=September 2, 2003 | work=Business Wire}}</ref><ref>{{cite web |author=Johnson & Johnson |author-link=Johnson & Johnson |title=Building on a foundation of health |url=http://files.shareholder.com/downloads/JNJ/0x0x180977/C0E8971E-DC6F-4DB2-AF7E-00ED716010C8/jnj_2003annual.pdf |publisher=Shareholder |year=2003 |url-status=dead |archive-url=https://web.archive.org/web/20111001135049/http://files.shareholder.com/downloads/JNJ/0x0x180977/C0E8971E-DC6F-4DB2-AF7E-00ED716010C8/jnj_2003annual.pdf |archive-date=2011-10-01 |access-date=2009-05-15 }}</ref> Johnson & Johnson menarik permohonan pemasarannya pada tahun 2009.<ref>{{cite web |title=Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications |url=https://www.fda.gov/ohrms/dockets/98fr/E9-11628.htm |publisher=Federal Register 74(95):23407-23412 |date=May 19, 2009 |quote=see also FDA docket number FDA-2009-N-0211 |url-status=live |archive-url=https://web.archive.org/web/20160919181749/https://www.fda.gov/ohrms/dockets/98fr/E9-11628.htm |archive-date=September 19, 2016 }}</ref>
